StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

StockNews.com started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Saturday. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets lowered their target price on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a report on Monday, November 11th.

NovaBay Pharmaceuticals Trading Up 4.0 %

NBY stock opened at $0.64 on Friday. The business’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.87. NovaBay Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $9.08. The firm has a market capitalization of $3.15 million, a PE ratio of -0.01 and a beta of 0.65.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.